ASH 2012

 

ASH 2012 Video Coverage

Live Coverage from ASH 2012

ASH 2012

ASH: Ferumoxytol Increases Hemoglobin, Iron Parameters, in Patients with Iron Deficiency Anemia

Patients with IDA with a history of unsatisfactory oral iron therapy appear to benefit from treatment with IV ferumoxytol.

ASH 2012

ASH: Patients with Mantle Cell Lymphoma Treated with Ibrutinib Have Durable Responses

The oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has an "unprecedented single agent overall response rate" in patients with relapsed or refractory mantle cell lymphoma (MCL), interim results of a global phase 2 study reported during the 54th American Society of Hematology Annual Meeting and Exposition.

ASH 2012

ASH: First-Line Oral Proteasome Inhibitor MLN9708 Shows High Response Rates in Multiple Myeloma

The combination of the investigational weekly oral, proteasome inhibitor, MNL9708, plus standard dose lenalidomide and dexamethasone has antitumor activity at the recommended phase 2 dose in treatment-naïve patients with multiple myeloma, investigators reported at the 54th American Society of Hematology Annual Meeting and Exposition.

ASH 2012

ASH: Asparaginase Erwinia Chrysanthemi 'Well Tolerated' Among Patients with ALL and L-ASP Allergy

Asparaginase Erwinia chrysanthemi (marketed as Erwinaze) is well tolerated among children and young adults diagnosed with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to the Escherichia coli-derived L-asparaginase (L-ASP), according to compassionate use protocol data presented during the 54th American Society of Hematology Annual Meeting and Exposition. L-ASP is part of standard chemotherapy regimens for ALL.

ASH 2012

ASH: Aspirin Might Improve Survival in Refractory and Relapsed CLL

Adding aspirin therapy to FCR (fludarabine, cyclophosphamide and rituximab) improves outcomes for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to a single-institution study presented during the 54th American Society of Hematology Annual Meeting and Exposition.

ASH 2012

ASH: PACE: Superior Molecular Response to Ponatinib in Chronic Myeloid Leukemia (CML)

Ponatinib treatment is associated with significant molecular response rates among patients intolerant to dasatinib and nilotinib or who have dasatimib- and nilotinib-resistant chronic myeloid leukemia (CML), according to an analysis of data from the open-label multinational phase 2 PACE clinical trial. The analysis was presented during the 54th American Society of Hematology Annual Meeting and Exposition.

ASH 2012

ASH: Wide Variability Observed in Antifungal Use for Pediatric AML

Wide variability across U.S. children's hospitals in antifungal use for pediatric acute myeloid leukemia (AML) does not appear to correlate with induction case fatality rates, according to a study presented during the 54th American Society of Hematology Annual Meeting and Exposition.

ASH 2012

ASH: Higher Imatinib Exposures Associated with Better Chronic-Phase CML Outcomes

Among chronic myeloid leukemia (CML) patients, higher imatinib exposures were associated with better overall survival (OS) and event-free survival (EFS), according to an analysis of data from the WORLD CML Registry presented during the 54th American Society of Hematology Annual Meeting and Exposition.

ASH 2012

ASH: Ponatinib Active in CML, Ph+ ALL Resistant to Dasatinib or Nilotinib

Ponatinib has substantial activity and is generally well tolerated in heavily pretreated patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation.

ASH 2012

ASH: Quizartinib "Promising" for Relapsed, Refractory AML

Quizartinib is a promising treatment for refractory and relapsed acute myeloid leukemia (AML) after second-line chemotherapy or hematopoietic stem cell transplantation (HSCT), according to a cohort analysis of data from an open-label phase 2 safety and efficacy study presented during the 54th American Society of Hematology Annual Meeting and Exposition.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs